Los Angeles Capital Management
TRDA icon

Los Angeles Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Los Angeles Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45,952
Closed -$317K – 2609
2025
Q4 		$317K Sell
45,952
-6,127
-12% -$51.6K ﹤0.01% 1072
2025
Q3 		$302K Buy
52,079
+7,447
+17% +$43.6K ﹤0.01% 1126
2025
Q2 		$300K Buy
44,632
+16,840
+61% +$135K ﹤0.01% 1045
2025
Q1 		$251K Sell
27,792
-240
-0.9% -$2.99K ﹤0.01% 948
2024
Q4 		$485K Sell
28,032
-5,900
-17% -$107K ﹤0.01% 819
2024
Q3 		$542K Buy
+33,932
New +$535K ﹤0.01% 843

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Los Angeles Capital Management's TRDA Position: Q1 2026 in Review

Los Angeles Capital Management sold out of Entrada Therapeutics (TRDA) in Q1 2026, closing a stake of 45,952 shares — an estimated $317K sold.

Los Angeles Capital Management first reported a position in TRDA in Q3 2024 and held it in 6 quarters. The position peaked at $542K in Q3 2024. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Los Angeles Capital Management reported no remaining Entrada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Los Angeles Capital Management sold 45,952 Entrada Therapeutics shares in Q1 2026, an estimated $317K.
  • Los Angeles Capital Management first reported a position in Entrada Therapeutics in Q3 2024 and held it in 6 quarters.
  • Los Angeles Capital Management's Entrada Therapeutics position peaked at $542K in Q3 2024.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.